Atomic-AI
Atomic-AI
Generating BuzzAI platform for drug discovery and development, accelerating research with advanced computational tools.
About
Technology stack
detected 2026-06-29No comments yet. Be the first to share your take.
What does Atomic-AI do?
Atomic AI is developing RNA-centric medicines using a platform that fuses machine learning and structural biology. Their core product, the ATOM-1 foundation model, enables precise predictions of RNA 3D structure to unlock new therapeutic targets. They serve the field of drug discovery, focusing on RNA-targeted small molecules and RNA-based therapeutics.
How much funding has Atomic-AI raised?
Atomic-AI has raised a total of $6.2B in funding. The most recent round on record is Series A.
Where is Atomic-AI headquartered?
Atomic-AI is headquartered in San Francisco, United States.
When was Atomic-AI founded?
Atomic-AI was founded in 2022.
What industry does Atomic-AI operate in?
Atomic-AI operates in Biotech, Drug Discovery, AI-Driven Protein Design, Foundation Model, Generative AI, Machine Learning.
How many employees does Atomic-AI have?
Atomic-AI has approximately 30 people on record.